Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01328002 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
A Phase 2 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT01328002 is a Phase 2 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 116 participants.
The verdict
NCT01328002, a Phase 2 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
Interventions
- DRUG Placebo
- DRUG Milnacipran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2011-04-30 |
| Est. Completion | 2012-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01328002
The ClinicalTrials.gov registry entry for NCT01328002 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01328002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01328002 about?
NCT01328002 is a clinical study titled "Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia". The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
What is the current status of trial NCT01328002?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2011-04-30. Estimated completion is 2012-08-31.
What interventions are being tested in trial NCT01328002?
The interventions under investigation include: Placebo (DRUG), Milnacipran (DRUG).
Who is sponsoring clinical trial NCT01328002?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.